Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Shares Outstanding (Weighted Average): 2020-2024

Historic Shares Outstanding (Weighted Average) for Taysha Gene Therapies (TSHA) over the last 5 years, with Dec 2024 value amounting to $205.0 million.

  • Taysha Gene Therapies' Shares Outstanding (Weighted Average) rose 33.11% to $272.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $272.8 million, marking a year-over-year increase of 33.11%. This contributed to the annual value of $205.0 million for FY2024, which is 9.65% up from last year.
  • According to the latest figures from FY2024, Taysha Gene Therapies' Shares Outstanding (Weighted Average) is $205.0 million, which was up 9.65% from $187.0 million recorded in FY2023.
  • Taysha Gene Therapies' 5-year Shares Outstanding (Weighted Average) high stood at $205.0 million for FY2024, and its period low was $37.8 million during FY2020.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $151.5 million, with a median of $187.0 million in 2023.
  • Data for Taysha Gene Therapies' Shares Outstanding (Weighted Average) shows a peak YoY surged of 199.41% (in 2023) over the last 5 years.
  • Over the past 5 years, Taysha Gene Therapies' Shares Outstanding (Weighted Average) (Yearly) stood at $37.8 million in 2020, then increased by 1.89% to $38.5 million in 2021, then soared by 62.30% to $62.4 million in 2022, then soared by 199.41% to $187.0 million in 2023, then grew by 9.65% to $205.0 million in 2024.